O	0	7	Patient
O	7	8	-
O	8	16	Reported
O	17	25	Outcomes
O	26	33	Predict
O	34	45	Progression
O	45	46	-
O	46	50	Free
O	51	59	Survival
O	60	62	of
O	63	71	Patients
O	72	76	with
O	77	85	Advanced
O	86	92	Breast
O	93	99	Cancer
O	100	107	Treated
O	108	112	with
B-intervention	113	124	Abemaciclib
O	124	125	.

O	126	137	Abemaciclib
O	138	140	is
O	141	142	a
O	143	147	CDK4
O	147	148	/
O	148	149	6
O	150	159	inhibitor
O	160	164	used
O	165	167	to
O	168	173	treat
O	174	181	hormone
O	182	190	receptor
O	190	191	-
O	191	199	positive
O	199	200	,
O	201	206	human
O	207	216	epidermal
O	217	223	growth
O	224	230	factor
O	231	239	receptor
O	240	241	2
O	241	242	-
O	242	250	negative
O	251	259	advanced
O	260	266	breast
O	267	273	cancer
O	273	274	.

O	275	278	The
O	279	289	prognostic
O	290	295	value
O	296	298	of
O	299	306	patient
O	306	307	-
O	307	315	reported
O	316	324	outcomes
O	325	326	(
O	326	330	PROs
O	330	331	)
O	332	335	has
O	336	340	been
O	341	350	minimally
O	351	359	explored
O	360	363	for
O	364	373	treatment
O	374	382	outcomes
O	383	387	with
O	388	392	CDK4
O	392	393	/
O	393	394	6
O	395	405	inhibitors
O	405	406	.

O	407	410	The
O	411	422	performance
O	423	425	of
O	426	430	PROs
O	431	439	compared
O	440	444	with
O	445	452	Eastern
O	453	464	Cooperative
O	465	473	Oncology
O	474	479	Group
O	480	491	performance
O	492	498	status
O	499	500	(
O	500	504	ECOG
O	504	505	-
O	505	507	PS
O	507	508	)
O	509	511	is
O	512	519	unknown
O	519	520	.

O	521	525	This
O	526	531	study
O	532	538	pooled
O	539	543	data
O	544	548	from
O	549	555	single
O	555	556	-
O	556	559	arm
O	560	565	trial
O	565	566	,
O	567	574	MONARCH
O	575	576	1
O	576	577	,
O	578	581	and
O	582	592	randomized
O	593	599	trials
O	599	600	,
O	601	608	MONARCH
O	609	610	2
O	611	614	and
O	615	616	3
O	616	617	.

O	618	620	In
O	621	626	total
O	626	627	,
B-intervention-participants	628	631	900
O	632	640	patients
O	641	650	initiated
O	651	662	abemaciclib
O	663	666	and
B-control-participants	667	670	384
B-control	671	681	comparator
I-control	682	689	therapy
O	689	690	.

O	691	703	Pretreatment
O	704	707	PRO
O	708	719	association
O	720	724	with
O	725	736	progression
O	736	737	-
O	737	741	free
O	742	750	survival
O	751	752	(
O	752	755	PFS
O	755	756	)
O	757	760	was
O	761	768	modeled
O	769	774	using
O	775	778	Cox
O	779	791	proportional
O	792	799	hazards
O	800	810	regression
O	810	811	.

O	812	822	Prediction
O	823	834	performance
O	835	838	was
O	839	847	assessed
O	848	851	via
O	852	855	the
O	856	857	C
O	857	858	-
O	858	867	statistic
O	868	869	(
O	869	870	c
O	870	871	)
O	871	872	.

O	873	877	PROs
O	878	882	were
O	883	891	recorded
O	892	895	via
O	896	899	the
O	900	908	European
O	909	921	Organisation
O	922	925	for
O	926	934	Research
O	935	938	and
O	939	948	Treatment
O	949	951	of
O	952	958	Cancer
O	959	962	QLQ
O	962	963	-
O	963	966	C30
O	966	967	.

O	968	975	Patient
O	975	976	-
O	976	984	reported
O	985	993	physical
O	994	1002	function
O	1002	1003	,
O	1004	1008	pain
O	1008	1009	,
O	1010	1014	role
O	1015	1023	function
O	1023	1024	,
O	1025	1032	fatigue
O	1032	1033	,
O	1034	1037	and
O	1038	1046	appetite
O	1047	1051	loss
O	1052	1056	were
O	1057	1067	associated
O	1068	1072	with
O	1073	1076	PFS
O	1077	1079	on
O	1080	1091	univariable
O	1092	1095	and
O	1096	1104	adjusted
O	1105	1113	analysis
O	1114	1115	(
O	1115	1116	p
O	1117	1118	<
O	1119	1120	.
O	1120	1122	05
O	1122	1123	)
O	1123	1124	.

B-outcome	1125	1133	Physical
I-outcome	1134	1142	function
O	1143	1144	(
O	1144	1145	c
O	1146	1147	=
O	1148	1149	0
O	1149	1150	.
O	1150	1152	55
O	1152	1153	)
O	1154	1157	was
O	1158	1162	most
O	1163	1173	predictive
O	1173	1174	,
O	1175	1183	superior
O	1184	1186	to
O	1187	1191	ECOG
O	1191	1192	-
O	1192	1194	PS
O	1195	1196	(
O	1196	1197	c
O	1198	1199	=
O	1200	1201	0
O	1201	1202	.
O	1202	1204	54
O	1204	1205	)
O	1205	1206	,
O	1207	1211	with
O	1212	1225	multivariable
O	1226	1234	analysis
O	1235	1245	indicating
O	1246	1250	both
O	1251	1258	provide
O	1259	1270	independent
O	1271	1282	information
O	1283	1284	(
O	1284	1285	p
O	1286	1287	<
O	1288	1289	.
O	1289	1291	02
O	1291	1292	)
O	1292	1293	.

O	1294	1296	In
O	1297	1300	the
O	1301	1307	pooled
O	1308	1318	randomized
O	1319	1323	arms
O	1324	1326	of
O	1327	1334	MONARCH
O	1335	1336	2
O	1337	1340	and
O	1341	1342	3
O	1342	1343	,
O	1344	1347	the
B-outcome	1348	1351	PFS
O	1352	1361	treatment
O	1362	1369	benefit
O	1370	1371	(
O	1371	1377	hazard
O	1378	1383	ratio
O	1384	1385	[
O	1385	1387	95
O	1387	1388	%
O	1389	1399	confidence
O	1400	1408	interval
O	1408	1409	]
O	1409	1410	)
O	1411	1413	of
O	1414	1425	abemaciclib
O	1426	1427	(
O	1427	1429	vs
O	1429	1430	.
O	1431	1442	comparators
O	1442	1443	)
O	1444	1447	was
O	1448	1449	0
O	1449	1450	.
O	1450	1452	75
O	1453	1454	(
O	1454	1455	0
O	1455	1456	.
O	1456	1458	57
O	1458	1459	-
O	1459	1460	1
O	1460	1461	.
O	1461	1462	0
O	1462	1463	)
O	1464	1467	for
B-outcome	1468	1471	low
I-outcome	1472	1480	physical
I-outcome	1481	1489	function
O	1489	1490	,
O	1491	1499	compared
O	1500	1504	with
O	1505	1506	0
O	1506	1507	.
O	1507	1509	48
O	1510	1511	(
O	1511	1512	0
O	1512	1513	.
O	1513	1515	40
O	1515	1516	-
O	1516	1517	0
O	1517	1518	.
O	1518	1520	59
O	1520	1521	)
O	1522	1525	for
B-outcome	1526	1538	intermediate
I-outcome	1538	1539	/
I-outcome	1539	1543	high
O	1544	1545	(
O	1545	1546	p
O	1546	1547	[
O	1547	1558	interaction
O	1558	1559	]
O	1560	1561	=
O	1562	1563	.
O	1563	1565	01
O	1565	1566	)
O	1566	1567	.

O	1568	1572	PROs
O	1573	1577	were
O	1578	1588	identified
O	1589	1591	as
O	1592	1602	prognostic
O	1603	1610	factors
O	1611	1614	for
O	1615	1618	PFS
O	1619	1621	in
O	1622	1630	patients
O	1631	1641	initiating
O	1642	1653	abemaciclib
O	1653	1654	,
O	1655	1659	with
O	1660	1667	patient
O	1667	1668	-
O	1668	1676	reported
O	1677	1685	physical
O	1686	1694	function
O	1695	1705	containing
O	1706	1717	independent
O	1718	1728	predictive
O	1729	1740	information
O	1741	1747	beyond
O	1748	1752	ECOG
O	1752	1753	-
O	1753	1755	PS
O	1755	1756	.

O	1757	1760	Low
O	1761	1769	physical
O	1770	1778	function
O	1779	1782	was
O	1783	1793	associated
O	1794	1798	with
O	1799	1800	a
O	1801	1809	decrease
O	1810	1812	in
O	1813	1816	the
O	1817	1826	magnitude
O	1827	1829	of
O	1830	1833	PFS
O	1834	1841	benefit
O	1842	1846	from
O	1847	1858	abemaciclib
O	1858	1859	.

O	1860	1864	PROs
O	1865	1871	should
O	1872	1874	be
O	1875	1883	explored
O	1884	1886	as
O	1887	1897	prognostic
O	1897	1898	,
O	1899	1909	predictive
O	1909	1910	,
O	1911	1914	and
O	1915	1929	stratification
O	1930	1937	factors
O	1938	1941	for
O	1942	1950	clinical
O	1951	1954	use
O	1955	1958	and
O	1959	1967	research
O	1968	1974	trials
O	1975	1977	of
O	1978	1982	CDK4
O	1982	1983	/
O	1983	1984	6
O	1985	1995	inhibitors
O	1995	1996	.

O	1997	2000	For
O	2001	2004	the
O	2005	2010	first
O	2011	2015	time
O	2015	2016	,
O	2017	2029	pretreatment
O	2030	2037	patient
O	2037	2038	-
O	2038	2046	reported
O	2047	2055	outcomes
O	2056	2060	have
O	2061	2065	been
O	2066	2071	shown
O	2072	2074	to
O	2075	2077	be
O	2078	2089	independent
O	2090	2100	prognostic
O	2101	2108	markers
O	2109	2112	for
O	2113	2124	progression
O	2124	2125	-
O	2125	2129	free
O	2130	2138	survival
O	2139	2140	(
O	2140	2143	PFS
O	2143	2144	)
O	2145	2147	in
O	2148	2156	patients
O	2157	2166	diagnosed
O	2167	2171	with
O	2172	2179	hormone
O	2180	2188	receptor
O	2188	2189	-
O	2189	2197	positive
O	2197	2198	,
O	2199	2204	human
O	2205	2214	epidermal
O	2215	2221	growth
O	2222	2228	factor
O	2229	2237	receptor
O	2238	2239	2
O	2239	2240	-
O	2240	2248	negative
O	2249	2250	(
O	2250	2252	HR
O	2252	2253	+
O	2253	2254	/
O	2254	2258	HER2
O	2258	2259	-
O	2259	2260	)
O	2261	2269	advanced
O	2270	2276	breast
O	2277	2283	cancer
O	2284	2291	treated
O	2292	2296	with
O	2297	2308	abemaciclib
O	2308	2309	.

O	2310	2321	Importantly
O	2321	2322	,
O	2323	2331	patients
O	2332	2336	with
O	2337	2340	low
O	2341	2349	physical
O	2350	2358	function
O	2359	2362	had
O	2363	2364	a
O	2365	2372	smaller
O	2373	2376	PFS
O	2377	2384	benefit
O	2385	2389	from
O	2390	2401	abemaciclib
O	2402	2403	(
O	2403	2405	vs
O	2405	2406	.
O	2407	2417	comparator
O	2417	2418	)
O	2419	2423	than
O	2424	2432	patients
O	2433	2437	with
O	2438	2450	intermediate
O	2450	2451	/
O	2451	2455	high
O	2456	2464	physical
O	2465	2473	function
O	2473	2474	.

O	2475	2478	The
O	2479	2486	present
O	2487	2492	study
O	2493	2505	demonstrates
O	2506	2513	patient
O	2513	2514	-
O	2514	2522	reported
O	2523	2531	outcomes
O	2532	2534	as
O	2535	2536	a
O	2537	2543	simple
O	2543	2544	,
O	2545	2554	effective
O	2554	2555	,
O	2556	2567	inexpensive
O	2567	2568	,
O	2569	2572	and
O	2573	2584	independent
O	2585	2595	prognostic
O	2596	2602	marker
O	2603	2606	for
O	2607	2615	patients
O	2616	2620	with
O	2621	2623	HR
O	2623	2624	+
O	2624	2625	/
O	2625	2629	HER2
O	2629	2630	-
O	2631	2639	advanced
O	2640	2646	breast
O	2647	2653	cancer
O	2654	2661	treated
O	2662	2666	with
O	2667	2678	abemaciclib
O	2678	2679	.
